Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenocarcinoma

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 5163-5168

  Fujiwara, Yuki ^a   Misawa, Takeyuki ^a   Shiba, Hiroaki ^a   Shirai, Yoshihiro ^a   Iwase, Ryota ^a   Haruki, Koichiro ^a   Furukawa, Kenei ^a   Futagawa, Yasuro ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lymphocyte to monocyte ratio; Pancreatic adenocarcinoma; Pancreatic resection; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FRESH FROZEN PLASMA; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NAFAMSTAT MESILATE;

ADULT; AGED; ARTICLE; BLOOD CELL RATIO; BODY MASS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ERYTHROCYTE CONCENTRATE; FEMALE; FOLLOW UP; HUMAN; LUNG COMPLICATION; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIMODALITY CANCER THERAPY; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS RESECTION; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PERIOPERATIVE PERIOD; PERIPHERAL ABSOLUTE BLOOD LYMPHOCYTE TO MONOCYTE RATIO; PLASMA TRANSFUSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SURGICAL INFECTION; ADENOCARCINOMA; BLOOD; LEUKOCYTE COUNT; LYMPHOCYTE-TO-MONOCYTE RATIO; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PANCREATIC RESECTION; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

LYMPHOCYTE-TO-MONOCYTE RATIO; PANCREATIC ADENOCARCINOMA; PANCREATIC RESECTION; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSTOPERATIVE PERIOD; PROGNOSIS; TREATMENT OUTCOME;

EID: 84908680711     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Evans DB, Abbruzzesse JL and Willett CG;Cancer of the pancreas. In: De Vita VT, Hellman S, Rosenberg SA (eds.). Cancer-Principles and Practice of Oncology. 6th ed. Lippincott Williams and Wilkins, Philadelphia pp. 1126-1161, 2001.
2. Sohn TA, Yeo CJ, Cameron JL Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemore KD; Resected adenocarcinoma of the pancreas-616 patients; results, outcome, and prognostic indicators. J Gastrointest Surg 4: 567-579, 2000.
3. Cameron JL, Riall TS, Coleman J and Belcher K; One thousand consective pancreaticoduodenectomies. Ann Surg 244: 10-15, 2006.
4. Han SS, Jang JY, Kim SW, Lee KU and Park YH: Analysis of long-term suvivors after resection for pancreatic cancer. Pancreas 32: 271-275, 2006.
5. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA and Lillemoe KD: A marginnegative R0 resection accomplished with minimal postoperative is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 10: 1338-1345, 2006.
6. Mapara MY and Sykes M: Tolerance and cancer: mechanisms of tumour evasion and strategies for breaking tolerance. J Clin Oncol 22: 1136-1151, 2004.
7. Liyanage UK, Moore TT, Joo H-G, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Srasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC: Prevalence of regulatory Tcells is increasing in peripheral blood and tumour microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002.
8. Roxburgh CS and McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149-163, 2010.
9. McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223-226, 2009.
10. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV and Rahman SH: Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Fur J Surg Oncol 35: 605-610, 2009.
11. Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K, Iida T, Iwase R and Yanaga K; Negative Impact of Fresh-frozen Plasma Transfusion on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Anticancer Res 33: 4041-4047, 2013.
12. Japan Pancreas Society. General rules for the study of pancreatic cancer, 6th ed. (in Japanese). Tokyo: Kanehara; 2009.
13. Uwagawa T, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S and Yanaga K: Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Am J Clin Oncol 36: 44-48, 2013.
14. Bassi C, Dervenis C, Butturini G, Fingerhunt A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W and Buchler M: International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138: 8-13, 2005.
15. Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, Polignano FM and Tait IS: Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 13: 199-204, 2012.
16. Elias EG, Leuchten JM, Buda BS and Brown SD: Prognostic value of initial mononucleated cell percentages in patients with epidermoid carcinoma of the head and neck. Am J Surg 152: 487-490, 1986.
17. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M and Kitano S: Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery 139: 755-764, 2006.
18. Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, Okunaga R, Shibata K, Ohta M and Kitano S: Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg 11: 596-602, 2007.
19. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C and Markovic SN: Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocytepredominant Hodgkin lymphoma. Br J Haematol 157: 321-330, 2012.
20. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C and Markovic SN: Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 97: 262-269, 2012.
21. Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, Balleari E, Musto P, Neri S, Aloe Spiriti MA and Cox MC: Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 21: 1486-1491, 2010.
22. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN and Porrata L: The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25: 1502-1509, 2011.
23. + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434, 2006.
24. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980, 1998.